ABSTRACT
Bangladesh is located in Southeast Asia that has a high population density. It is a lower-middle-income country. The COVID-19 pandemic severely impacted the nation that slowed its economic growth. It halted major industries, crippling the nation's economy. The students were uncertain after the declaration of school closures. Hospitals could not treat other patients properly due to the vast health burden of COVID-19. Bangladesh put up a solid fight during COVID-19 as a lower-middle-income country. Prompt action, early vaccination drives, effective awareness campaigns, and widespread public involvement have enabled Bangladesh to bring more than 90% of its population into COVID-19 vaccination coverage. It was possible by the effective diplomatic and local health strategy implemented by the Bangladeshi government, the country's extensive prior experience, and its long history of achieving a high success rate in other vaccination campaigns. Bangladesh was able to flatten the curve sooner than other developed countries. Therefore, the cogs of everyday social life and the economy begin to turn once more. The strategy Bangladesh used to combat the COVID-19 pandemic through vaccination and diplomatic policy by calling on its prior experience has the potential to serve as a model for other low- and middle-income countries and an example for developed nations.
ABSTRACT
In response to the raging COVID-19 pandemic, Bangladesh started its vaccine administration in early 2021; however, due to the rapid development and launch of the vaccines in the market, many people had concerns regarding the safety of these vaccines. The purpose of this study was to evaluate the side effects that were experienced by the Bangladeshi residents after receiving the first dose of the Oxford-AstraZeneca's Covishield vaccine (ChAdOx1nCoV-19). The study was conducted using both online and printed questionnaires and the data were analysed using SPSS. The results included the responses of 474 vaccine recipients from March-April 2021. Pain at the site of injection, fever, myalgia, fatigue and headache were the most commonly reported symptoms, and the overall side effects were found to be significantly more prevalent in the younger population (p ≤ 0.05). These findings were consistent with the results indicated by the clinical trial of ChAdOx1nCoV-19. Logistic regression analysis further revealed that compared to people aged 70 years or above, the incidence of reported side effects was significantly higher in people aged 18-30 years (odds ratio (OR) = 8.56), 31-40 years, (OR = 5.05), 41-50 years (OR = 4.08), 51-60 years (OR = 3.77) and 61-70 years (OR = 3.67). In addition, a significantly higher percentage of female participants suffered from post-vaccination side effects compared to males (OR = 1.51). It was concluded that the Covishield vaccine was well-tolerated among people of different age groups. Nevertheless, further long-term follow-up study with a larger sample size is warranted to establish the long-term safety of the COVID-19 vaccine.